Discordant humoral and cellular immune responses to cytomegalovirus (CMV) in glioblastoma patients whose tumors are positive for CMV

OncoImmunology

Volumn 4, Issue 2, 2015, Pages 1-8

  Rahbar, Afsar ^a   Peredo, Inti ^b   Solberg, Nina Wolmer ^a   Taher, Chato ^a   Dzabic, Mensur ^a   Xu, Xinling ^a   Skarman, Petra ^a   Fornara, Olesja ^a   Tammik, Charlotte ^a   Yaiw, Koon ^a   Wilhelmi, Vanessa ^a   Assinger, Alice ^a   Stragliotto, Giuseppe ^b   Söderberg Naucler, Cecilia ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytomegalovirus; Glioblastoma; Peptides stimulation; Serology; Valganciclovir

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PLACEBO; TEMOZOLOMIDE; VALGANCICLOVIR;

ANTIVIRAL THERAPY; ARTICLE; CD3+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOMEGALOVIRUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROLOGY;

EID: 84944448592     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.982391     Document Type: Article

References (47)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC- NCIC trial. Lancet Oncol 2009;10:459-66;PMID:19269895;http://dx.doi.org/10.1016/S1470-2045(09)70025-7
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96;PMID:15758009
3. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 2002;62: 3347-50;PMID:12067971
4. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncol 2008;10:10-18;PMID:17951512
5. Ranganathan P, Clark PA Kuo JS, Salamat MS, Kalejta RF. Significant association of multiple human cytomegalovirus genomic loci with glioblastoma multiforme samples. J Virol 2012;86:854-64;PMID:22090104; http://dx.doi.org/9.10.1128/JVI.06097-11
6. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 2008;116:79-86;PMID:18351367;http://dx.doi.org/10.1007/s00401-008-0359-110.
7. Rahbar A, Orrego A, Peredo I, Dzabic M, Wolmer-Solberg N, Straat K et al. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J Clin Virol 2013;57(1):36-42;PMID:23391370;http://dx.doi.org/10.1016/j.jcv.2012.12.018
8. Libard S, Popova SN, Amini RM, Karja V, Pietilainen T, Hamalainen KM, Sundstrom C, Hesselager G, Bergqvist M, Ekman S et al. Human cytomegalovirus tegument protein pp65 is detected in all intra- and extra-axial brain tumours independent of the tumour type or grade. PloS One 2014;9:e108861;PMID:25268364;http://dx.doi.org/10.1371/journal.pone.0108861
9. Rahbar A, Stragliotto G, Orrego A, Peredo I, Taher C, Willems J, Soderberg-Naucler C et al. Low levels of human cytomegalovirus infection in glioblastoma multiforme associates with patient survival;-a case-control study. Herpesviridae 2012;3:3;PMID:22424569; http://dx.doi.org/10.1186/2042-4280-3-3
10. Bongers G, Maussang D, Muniz LR, Noriega VM, Fraile-Ramos A, Barker N, Marchesi F, Thirunarayanan N, Vischer HF, Qin L et al. The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J Clin Invest 2010;120:3969-78;PMID:20978345; http://dx.doi.org/10.1172/JCI42563
11. Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med 2006;259:21946;PMID:16476101
12. Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res 2011;157:193-203;PMID:21036194;http://dx.doi.org/10.1016/j.virusres.2010.10.026
13. Michaelis M, Doerr HW, Cinatl J, Jr. Oncomodulation by human cytomegalovirus: evidence becomes stronger. Med Microbiol Immunol 2009;198:79-81;PMID:19198878;http://dx.doi.org/10.1007/s00430-009-0107-8
14. John Inge Johnsen, Ninib Baryawno, Soderberg-Naucler C. Is human cytomegalovirus a target in cancer therapy? Oncotarget 2011;2(12):1329-38;PMID:2246171
15. Stragliotto G, Rahbar A, Solberg NW, Lilja A, Taher C, Orrego A, Bjurman B, Tammik C, Skarman P, Peredo I et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis generating study. Int J Cancer 2013;133(5):1204-13;PMID:23404447;http://dx.doi.org/10.1002/ijc.28111
16. Soderberg-Naucler C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med 2013;369:985-6;PMID:24004141;http://dx.doi.org/10.1056/NEJMc 1302145
17. Rahbar AR, Sundqvist VA, Wirgart BZ, Grillner L, Soderberg-Naucler C. Recognition of cytomegalovirus clinical isolate antigens by sera from cytomegalovirus- negative blood donors. Transfusion 2004;44:1059-66;PMID:15225248
18. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 1997;91:119-26;PMID:9335340
19. Roback JD, Hillyer CD, Drew WL, Laycock ME, Luka J, Mocarski ES, Slobedman B, Smith JW, Soderberg-Naucler C, Todd DS et al. Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors. Transfusion 2001;41:1249-57;PMID:11606824
20. Bianchi E, Roncarati P, Hougrand O, Guerin-El Khourouj V, Boreux R, Kroonen J, Martin D, Robe P, Rogister B, Delvenne P et al. Human cytomegalovirus and primary intracranial tumors: frequency of tumor infection and lack of correlation with systemic immune anti-viral responses. Neuropathol Appl Neurobiol 2014;PMID:25041908;http://dx.doi.org/10.1111/nan.12172
21. Sester M, Gartner BC, Sester U, Girndt M, Mueller-Lantzsch N, Kohler H. Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation 2003;76:1229-30;PMID:14578758
22. Loeth N, Assing K, Madsen HO, Vindelov L, Buus S, Stryhn A. Humoral and cellular CMV responses in healthy donors;identification of a frequent population of CMV-specific, CD4+ T cells in seronegative donors. PloS one 2012;7:e31420;PMID:22347475;http://dx.doi.org/10.1371/journal.pone.0031420
23. Zhu J, Shearer GM, Marincola FM, Norman JE, Rott D, Zou JP, Epstein SE. Discordant cellular and humoral immune responses to cytomegalovirus infection in healthy blood donors: existence of a Th1- type dominant response. Int Immunol 2001;13:78590;PMID:11369706
24. Posavad CM, Wald A, Hosken N, Huang ML, Koelle DM, Ashley RL, Corey L. T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity? J Immunol 2003;170:4380-8;PMID:12682275
25. Posavad CM, Remington M, Mueller DE, Zhao L, Magaret AS, Wald A, Corey L. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol 2010;184:3250-9;PMID:20164419;http://dx.doi.org/10.4049/jimmunol.0900722
26. Long D, Skoberne M, Gierahn TM, Larson S, Price JA, Clemens V, Baccari AE, Cohane KP, Garvie D, Siber GR et al. Identification of novel virus-specific antigens by CD4(+) and CD8(+) T cells from asymptomatic HSV-2 seropositive and seronegative donors. Virology 2014;464-465:296-311; PMID:25108380; http://dx.doi.org/10.1016/j.virol.2014.07.018
27. Clerici M, Levin JM, Kessler HA, Harris A, Berzofsky JA, Landay AL, Shearer GM. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. Jama 1994;271:42-6;PMID:8258885
28. Rowland-Jones SL, McMichael A. Immune responses in HIV-exposed seronegatives: have they repelled the virus? Curr Opin Immunol 1995;7:448-55;PMID:7495507
29. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995;1:59-64;PMID:7584954
30. Pattacini L, Murnane PM, Kahle EM, Bolton MJ, Delrow JJ, Lingappa JR et al. Differential regulatory T cell activity in HIV type 1-exposed seronegative individuals. AIDS Res Hum Retroviruses 2013;29:1321-9;PMID:23815575;http://dx.doi.org/10.1089/AID.2013.0075
31. Murashev BV, Nazarenko OV, Akulova EB, Artemyeva AK, Verevochkin SV, Shaboltas AV, Skochilov RV, Toussova OV, Kozlov AP. The high frequency of HIV type 1-specific cellular immune responses in seronegative individuals with parenteral and/or heterosexual HIV type 1 exposure. AIDS Res Hum Retroviruses 2012;28:1598-605; PMID:22475222; http://dx.doi.org/10.1089/AID.2011.0335
32. Li L, Liu Y, Bao Z, Chen L, Wang Z, Li T, Li H, Zhuang D, Liu S, Wang X et al. Analysis of CD4+CD25+Foxp3+ regulatory T cells in HIV- exposed seronegative persons and HIV-infected persons with different disease progressions. Viral Immunol 2011;24:57-60;PMID:21319979;http://dx.doi.org/10.1089/vim.2010.0079
33. Prodger JL, Hirbod T, Gray R, Kigozi G, Nalugoda F, Galiwango R, Reynolds SJ, Huibner S, Wawer MJ, Serwadda D et al. HIV infection in uncircumcised men is associated with altered CD8 T-cell function but normal CD4 T-cell numbers in the foreskin. J Infect Dis 2014;209:1185-94;PMID:24277744; http://dx.doi.org/10.1093/infdis/jit644
34. Restrepo C, Rallon NI, del Romero J, Rodriguez C, Sempere-Ortells JM, de la Vega E, Soriano V, Benito JM. HIV Gag-specific immune response mediated by double negative (CD3(+)CD4(-)CD8(-)) T cells in HIV-exposed seronegative individuals. J Med Virol 2013;85:200-9;PMID:23172685;http://dx.doi.org/10.1002/jmv.23447
35. Abdelwahab SF, Zakaria Z, Sobhy M, Rewisha E, Mahmoud MA, Amer MA, Del Sorbo M, Capone S, Nicosia A, Folgori A et al. Hepatitis C virus-multispecific T-cell responses without viremia or seroconversion among Egyptian health care workers at high risk of infection. Clin Vaccine Immunol: CVI 2012;19: 780-6;PMID:23172685;http://dx.doi.org/10.1002/jmv.23447
36. Cameron B, Galbraith S, Li H, Lloyd A. Correlates and characteristics of hepatitis C virus-specific T-cell immunity in exposed uninfected high-risk prison inmates. J Viral Hepat 2013;20:e96-106;PMID:23490396;http://dx.doi.org/10.1111/jvh.12016
37. Scognamiglio P, Accapezzato D, Casciaro MA, Cacciani A, Artini M, Bruno G, Chircu ML, Sidney J, Southwood S, Abrignani S et al. Presence of effector CD8+ T cells in hepatitis C virus-exposed healthy seronegative donors. J Immunol 1999;162:6681-9;PMID:10352286
38. Wiegand J, Meya S, Schlaphoff V, Manns MP, Mossner J, Wedemeyer H, Tillmann HL. HBV-specific T- cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. J Viral Hepat 2010;17:631-9;PMID:19889141;http://dx.doi.org/10.1111/j.1365-2893.2009.01220.x
39. Elliott SP. Congenital cytomegalovirus infection: an overview. Infect Disord Drug targets 2011;11:432-6;PMID:21827436
40. Malm G, Engman ML. Congenital cytomegalovirus infections. Semin Fetal Neonatal Med 2007;12:154-9;PMID: 17337260
41. Hamprecht K, Goelz R, Maschmann J. Breast milk and cytomegalovirus infection in preterm infants. Early Hum Dev 2005;81:989-96;PMID:16278059
42. Ahlfors K. IgG antibodies to cytomegalovirus in a normal urban Swedish population. Scand J Infect Dis 1984;16:335-7;PMID:6098960
43. Shacklett BL. Understanding the “lucky few:”the conundrum of HIV-exposed, seronegative individuals. Curr HIV/AIDS Rep 2006;3:26-31;PMID:16522256
44. Mason GM, Jackson S, Okecha G, Poole E, Sissons JG, Sinclair J, Wills MR. Human cytomegalovirus latency- associated proteins elicit immune-suppressive IL-10 producing CD4(+) T cells. PLoS pathogens 2013;9: e1003635;PMID:24130479;http://dx.doi.org/10.1371/journal.ppat.1003635
45. Grillner L. Screening of blood donors for cytomegalovirus (CMV) antibodies: an evaluation of different tests. J Virol Methods 1987;17:133-9;PMID:2822749
46. Schmitz H, Doerr HW, Kampa D, Vogt A. Solid-phase enzyme immunoassay for immunoglobulin M antibodies to cytomegalovirus. J Clin Microbiol 1977;5:62934;PMID:195977
47. Soderberg C, Larsson S, Bergstedt-Lindqvist S, Moller E. Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection. J Virol 1993;67:3166-75;PMID:7684461